The Novavax COVID-19 vaccine could finally take a big step forward in the United States.
Intercept Pharmaceuticals stock could soon soar on the back of phase 3 data for its lead drug, Ocaliva, as a potential treatment for non-alcoholic steatohepatitis.
Madrigal Pharmaceuticals is another biotech with a treatment candidate expected to produce late-stage clinical trial data in January.
